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Dublin 4, IrelandToll-like receptors (TLRs) are crucially important in the
sensing of infectious agents. They serve to recognize
pathogen-associated molecules and respond by trigger-
ing the induction of specific profiles of proteins that are
tailored to the successful removal of the invading
pathogens. The induction of TLR-responsive genes is
mediated by the activation of transcription factors, and
most interest has focussed on NF-kB, a transcription
factor that is universally used by all TLRs. However,
there has recently been a burgeoning effort to increase
our appreciation of the importance of members of the
interferon-regulatory factor (IRF) family in TLR signal-
ling. This review will discuss the most recent findings
relating to the regulation of IRF activity by TLRs and will
highlight the rapidly increasing complexity of TLR
signalling pathways.
Introduction
Human Toll-like receptors (TLRs) act at the host–
pathogen interface and are the earliest surveillance
systems for primary infection by pathogens. To date,
11 TLRs have been identified and demonstrated to
recognize a variety of pathogen-associated molecular
patterns (PAMPs). The engagement of TLRs by patho-
genic components results in the induction of specific gene
expression profiles that are suited to ensuring efficient
removal and destruction of the invading pathogen. The
repertoire of TLR-responsive genes range from proinflam-
matory cytokines and interferons (IFNs) (which orches-
trate innate immunity) to co-stimulatory molecules (which
promote T-cell activation and specific immunity). The
capacity of TLRs to trigger the induction of tailored
profiles of genes is underpinned by their ability to activate
a variety of transcription factors. Much interest has
focussed on NF-kB, a transcription factor that is activated
by all TLRs. However, many recent studies have high-
lighted specific members of the IFN-regulatory factor
(IRF) family as crucial factors in the induction of
TLR-responsive genes. This review will give an overview
of the role of IRFs in TLR signalling and recent advances
in the identification of key signalling molecules used by
TLRs for the activation of IRFs.Corresponding author: Moynagh, P.N. (P.Moynagh@ucd.ie).
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Recent studies in relation to TLR signal transduction and
IRF activation have emphasized dual roles for signalling
molecules, with respect to triggering activation of both the
NF-kB andIRFpathways. Indeed, someof the keysignalling
molecules that mediateTLRactivationof IRFswere initially
discovered based on their ability to activate NF-kB. Thus, an
initial overview of the various TLR signalling pathways that
activate NF-kB forms a suitable context for discussion of
recent advances in TLR activation of IRFs.
Myd88-dependent signalling and activation of NF-kB
TLRs use many of the same signalling components as the
IL-1 receptor (IL-1R) as a result of their intracellular
regions sharing a conserved Toll–IL-1R (TIR) domain [1].
The proximal signalling events subsequent to TLR
engagement by an appropriate ligand have been well
characterised (Figure 1). With the exception of TLR3, all
TLRs recruit the TIR domain-containing adaptor molecule
myeloid differentiation factor 88 (Myd88) [2]. Myd88 then
associates with members of the IL-1R-associated kinase
(IRAK) family (IRAK-1–4) [1]. IRAK-1 is recruited to
Myd88 within a complex with another protein termed Toll-
interacting protein (Tollip) [3]. The IRAK–Myd88 associ-
ation triggers hyperphosphorylation of IRAK-1 by itself
and other kinases, such as IRAK-4 [4,5], which leads to its
dissociation from Myd88 and Tollip and its interaction
with the downstream adaptor tumour necrosis factor
(TNF) receptor-associated factor 6 (TRAF-6) [3]. TRAF-6
is an ubiquitin ligase [6,7] and activates transforming
growth factor-b (TGF-b)-activating kinase (TAK1) [8],
which in turn promotes downstream activation of the
IkB kinases (IKK), IKKa and IKKb. The IKKs directly
phosphorylate members of the inhibitory IkB family,
which normally sequester NF-kB in an inactive form in
the cytosol [9]. The phosphorylation of the IkB proteins
represents a signal for polyubiquitination followed by
their degradation by the 26 S proteosome and this enables
the translocation of NF-kB to the nucleus, where it
induces a plethora of genes encoding proinflammatory
proteins and co-stimulatory molecules [10,11].
Myd88-independent signalling and activation of NF-kB
With the exception of TLR3, the above pathway is used
universally by all TLRs in activating NF-kB and has beenReview TRENDS in Immunology Vol.26 No.9 September 2005. doi:10.1016/j.it.2005.06.009
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Figure 1. Regulation of IRFs and NF-kB by TLR3 and TLR4. TLR4 uses Myd88-dependent and -independent pathways to activate NF-kB. This results in the phosphorylation (P)
of the inhibitory IkB proteins, enabling the translocation of NF-kB into the nucleus. Themost common form of active NF-kB is a heterodimer consisting of the protein subunits
p50 and p65 and this complex induces the expression of proinflammatory genes. The Myd88-independent pathway uses TRIF, through the bridging adaptor TRAM, to
activate NF-kB in either a TRAF-6-dependent manner or a TRAF-6-independent mechanism (possibly involving RIP1). TRIF also associates with TBK1 and IKK-I, which in turn
phosphorylate IRF3 and IRF7, leading to their nuclear translocation and induction of type I IFN genes and co-stimulatorymolecules. TLR3 interacts directly with TRIF to trigger
these Myd88-independent pathways. In addition, TLR3 interacts with PI3K and activates Akt, leading to further phosphorylation and maximal activation of IRF3 and IRF7.
Review TRENDS in Immunology Vol.26 No.9 September 2005470termed Myd88-dependent signalling [12]. TLR3 signals in a
Myd88-independentmanner. Interestingly, the TLR4ligand
lipopolysaccharide (LPS) can still trigger activation of
NF-kB in Myd88-deficient mice, albeit with delayed kinetics
compared with wild-type cells, whereasmost other TLRs are
completely ineffective at activating NF-kB in these mice
[13]. Although Myd88-deficient mice lose their ability to
produce proinflammatory cytokines, such as TNF, IL-1, IL-6
and IL-12 p40, in response to LPS, they retain their capacity
to produce IFN-inducible genes and co-stimulatory mol-
ecules and their dendritic cells (DCs) mature in response to
LPS [14,15]. These studies define two arms of the LPS
signalling pathway: a Myd88-dependent component that
promotes fast activation of NF-kB and induction of
proinflammatory molecules and a Myd88-independent
pathway (also used by TLR3) that mediates slow activation
of NF-kB and induction of IFN-inducible genes and co-
stimulatory molecules (Figure 1).
A second TIR domain-containing adaptor protein was
identified by two independent groups, and was named
MyD88 adaptor-like (Mal), also known as TIR domain-
containing adaptor protein (TIRAP) [16,17]. However, the
generation of Mal (TIRAP) knockout mice showed thatwww.sciencedirect.comthis adaptor is not responsible for Myd88-independent
signalling and instead acts as a bridging adaptor between
Myd88 and TLR4 and TLR2 [18,19]. Subsequent studies
identified TIR domain-containing adaptor-inducing IFN-b
(TRIF), also known as TIR-containing adaptor molecule
(TICAM)-1, as the key regulator of the Myd88-independent
pathway. TRIF-knockout mice, or mice with a frame shift
mutation resulting in a truncated form of TRIF, fail to
show Myd88-independent activation of NF-kB and are
non-responsive to LPS or the TLR3 ligand poly(I:C), with
respect to the expression of IFN-inducible genes [20,21].
TRIF interacts directly with the TIR domain of TLR3 [22]
and mediates signalling, whereas another TIR domain-
containing adaptor TRIF-related adaptor molecule (TRAM),
also known as TICAM-2, acts as a bridging adaptor
between TLR4 and TRIF [23]. TRIF interacts with
TRAF-6, the downstream adaptor with a previously
described role in the Myd88-dependent pathway. How-
ever, there are contrasting reports on the importance of
TRAF-6 for mediating NF-kB activation by TRIF. The
mutation of the TRAF-6-binding site in TRIF reduces its
ability to activate NF-kB [24,25] and Jiang et al. [24] have
demonstrated that TLR3-induced NF-kB is completely
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mice. By contrast, Gohda et al. [26] have reported that
TLR3 activation of NF-kB is normal in TRAF-6-deficient
macrophages. The discrepancy might be owing to the
cell type-specific roles of TRAF-6 in TLR3 signalling or
functional redundancy of TRAF-6 in macrophages. Indeed,
TRIF can also associate with the kinase receptor-interacting
protein 1 (RIP1) and can activate NF-kB [27]; this might
facilitate TRAF-6-independent activation of NF-kB by
TLR3 in macrophages.
Activation of IRF3 and IRF7 by TLR3 and TLR4
The initial discovery of Myd88-independent pathways in
TLR signalling was predominantly based on the findings
that TLR3 and TLR4 ligands retain their ability to trigger
the expression of type I IFN and IFN-inducible genes in
Myd88-deficient mice [13,28]. Type I IFNs are encoded by
one IFN-b gene and multiple IFN-a genes. They comprise
potent antiviral molecules and it is easy to appreciate the
value of having virally derived double stranded (ds)RNA
induce their expression through TLR3. However, type I
IFNs also have an important role in bridging innate and
adaptive immunity by mediating the induction of co-
stimulatory molecules on antigen-presenting cells in
response to pathogen-associated molecules, such as LPS
[29]. Much interest has focussed on the regulatory
pathways that control the expression of type I IFNs.
In response to viral infection, IRF3 and IRF7 are the
most important transcription factors that regulate type I
IFN expression (reviewed in Ref. [30]). Prior to infection,
IRF3 is normally expressed at high constitutive levels in
most cells, whereas IRF7 is present at much lower levels.
Indeed, the central dogma is that IRF3 is responsible for
the early wave of IFN-b gene induction. IRF3 shuttles into
the nucleus by virtue of its nuclear localisation sequence;
however, it also possesses a nuclear export signal that
precludes high steady state nuclear levels of IRF3. Viral
infection triggers phosphorylation of a serine/threonine
cluster in the C-terminal region of IRF3. This causes a
change in conformation, revealing an IRF-association
domain and DNA-binding domain, enabling the dimeri-
zation of IRF3 and binding to IRF3 motifs in relevant
promoters. The C-terminal phosphorylation of IRF3 also
facilitates its association with the co-activators CBP
[CREB (cAMP response element-binding protein)-binding
protein] and p300 and these interactions prevent IRF3
export to the cytoplasm. IRF3 primarily activates the
IFN-b promoter with the co-operation of other transcrip-
tion factors, especially NF-kB. Once IFN-b is produced, it
subsequently activates a transcription factor complex,
known as IFN-stimulated gene factor 3 (ISGF3), compris-
ing STAT1 (signal transducer and activator of transcrip-
tion1), STAT2 and IRF9. ISGF3 in turn induces the
expression of IRF7 and this is subject to virus-induced
phosphorylation in a manner similar to IRF3. This leads to
activation of IRF7 and its stimulation of IFN-a/b
promoters. The induction of type I IFNs establishes a
positive feedback loop, ensuring high-level expression of
type I IFN and IFN-inducible genes.
Because TLR3 and TLR4 induce type I IFNs by
mechanisms independent of Myd88, recent attention haswww.sciencedirect.comfocussed on the mechanism by which TRIF induces type I
IFN and more specifically its ability to promote activation
of IRF3 and IRF7. The need for complete delineation of
this mechanism has become more pressing, with recent
reports showing that viruses have developed immune
evasion strategies including the sequestration of TRIF by
the viral protein A46R and the cleavage of TRIF by the
viral protease NS3/4a. These strategies are discussed in
more detail by Schro¨der and Bowie, also in this issue [31].
TBK1 and IKK-I activate IRF3 and IRF7
The engagement of TLR3 and TLR4 by poly(I:C) and LPS,
respectively, promotes phosphorylation of IRF3 and the
induction of type I IFN genes [14,32,33]. An intense
research effort culminated in key reports identifying two
kinases responsible for this phosphorylation [34,35]. Both
kinases are related to the IKK kinases and are inducible
IKK (IKK-i) (also known as IKK3) and TRAF family
member-associated NF-kB activator (TANK)-binding
kinase 1 (TBK1) [also called NF-kB-activating kinase
(NAK) or TRAF-2-associated kinase (T2K)]. Although the
overexpression of both forms is sufficient to activate NF-kB,
this is independent of the phosphorylation and degra-
dation of IkB proteins and is more related to the
phosphorylation and increased transactivation of the
NF-kB subunit p65 [36,37]. However, there is no definitive
report defining the physiological role of these kinases in
NF-kB signalling. Fitzgerald et al. [34] showed that IKK-i
and TBK1 mediate TLR3 and TRIF activation of IRF3
(Figure 1). Both IKK-i and TBK1 associate with TRIF
and a recent study has suggested that the TANK family
protein NAK-associated protein 1 (NAP1) might
facilitate the interaction of both kinases with TRIF [38].
The work of Fitzgerald et al. [34] suggests that there is a
TLR3–TRIF–IKK-I (TBK1)–IRF3 signalling axis. How-
ever, the study did not address the issue of whether IRF3
is a direct substrate for IKK-i and TBK1. A simultaneous
study by Sharma et al. [35] demonstrated that IKK-i and
TBK1 can directly phosphorylate IRF3 at its C-terminal
serine/threonine cluster and that this is sufficient to
induce nuclear translocation and DNA binding of IRF-3.
This has been independently confirmed [39]. Furthermore
IKK-i and TBK1 also phosphorylate and activate IRF7
similarly [35].
To study the in vivo function of IKK-i and TBK1,
relevant knockout mice were generated [37,40]. Deficiency
in TBK1 causes TNF-mediated liver degeneration, result-
ing in embryonic lethality [37]. However, embryonic
fibroblasts were generated from TBK1K/K mice, stimu-
lated with TLR3 and TLR4 ligands and characterised
relative to wild type cells, in relation to IRF3 activation
and induction of type I IFNs and IFN-inducible genes.
There was severe impairment of the activation and
nuclear translocation of IRF3 and induction of IFN-a,
IFN-b and IFN-inducible genes, such as RANTES and
IP10 (IFN-g-inducible protein 10), in response to both TLR
ligands [39,40]. Such defective TLR3 and TLR4 signalling
is also evident in bone marrow-derived macrophages
derived from TBK1K/KTNFR1K/K mice [41], further
emphasizing the crucial role of TBK1 in promoting
IRF3-dependent gene expression. The in vivo role of
Review TRENDS in Immunology Vol.26 No.9 September 2005472IKK-i in IRF3 signalling is less clear than that for TBK1.
Embryonic fibroblasts from IKK-iK/Kmice showed normal
responses todsRNA andLPS with respect to IRF3 activation
and induction of type I IFNs. However, IKKiK/KTBK1K/K
mice fail to express IFN genes or IFN-inducible genes in
response to dsRNA, and thus IKK-i might account for
the low residual expression of these genes still observed in
TBK1K/K cells [40]. Furthermore, reconstitution of
TBK1K/K cells with IKK-i can compensate partially for
the lack of TBK1, with respect to IRF3 activation and
induction of IFN-b. This suggests at least some degree of
functional redundancy between the two kinases in
activating IRF3. However, such redundancy might only
be relevant in specific cell types because TBK1 is produced
constitutively in all cells, whereas IKK-I production is
more restricted [41].
It is worth noting that the activation of NF-kB is
normal in response to dsRNA and LPS in TBK1K/K and
IKK-iK/K cells, demonstrating that TBK1 and IKK-i have
specific roles in mediating the activation of IRF3 and not
NF-kB in TLR3 and TLR4 pathways. Thus, a picture
emerges of a bifurcation into two distinct signalling
pathways downstream of TRIF (Figure 1). TRIF can
interact with TRAF-6, leading to classical activation of
NF-kB and the induction of proinflammatory proteins,
such as IL-1, IL-6 and TNF, whereas mutation of the
TRAF-6-binding site in TRIF fails to affect its ability to
activate IRF3. However, TRIF can also interact with
TBK1 to promote the activation of IRF3 and IRF7, leading
to the induction of type I IFN and IFN-inducible genes.
These two TRIF-mediated pathways are triggered by
TLR3 (through its direct interaction with TRIF), and
TLR4 by its indirect association with TRIF (through the
bridging adaptor TRAM) [42,43]. The concomitant acti-
vation of NF-kB and IRF3 by TRIF is of biological
significance because the activation of the promoters of
some genes, such as IFN-b, requires the functional co-
operation of these two transcription factors [44].
The downstream mechanism by which TRIF ultimately
activates IRF3 might differ between the TLR3 and TLR4
pathways because dsRNA causes phosphorylation of the
key serine residue 396 (Ser396) in the C-terminal region of
IRF3, whereas LPS fails to induce phosphorylation at this
site [33]. However, a more recent report has questioned
the importance of Ser396 as the primary phosphoacceptor
site and instead provides data to indicate that Ser386 is
the crucial residue that undergoes inducible phosphoryl-
ation, thus leading to IRF3 activation [45]. This study
provides a more satisfying mechanistic basis for TRIF
activation of IRF3 because both TBK1 and IKK-I can
phosphorylate IRF3 at Ser386 and the engagement of
TLR3 and TLR4 by dsRNA and LPS leads to phosphoryl-
ation of this residue.
TLR3 has been shown recently to be phosphorylated on
two key tyrosine residues in response to its engagement by
dsRNA and this leads to the recruitment of phosphatidyl-
inositol-3 kinase (PI3K), activation of the downstream
kinase Akt and ultimately phosphorylation of IRF-3 [46]
(Figure 1). The residue(s) phosphorylated by this Akt
pathway is not Ser396 and remains to be identified.
However, the phosphorylation has a key role in promotingwww.sciencedirect.comthe transactivation of IRF3 by facilitating its association
with the co-activator CBP. In light of the study by Mori
et al. [45], it would be interesting to determine if Ser386 is
the residue phosphorylated by Akt.
Because many viruses produce dsRNA as part of their
life cycle, the engagement of TLR3 by dsRNA and
subsequent activation of IRF3 and induction of type
IFNs is an important antiviral response in the host.
However, other virally sensing systems exist that are
independent of TLR3, yet activate IRF3 and induce IFNs.
One such system is the cytoplasmic RNA helicase retinoic
acid inducible gene I (RIG-I). It recognizes dsRNA and
activates IRF3 by a mechanism independent of TRIF but
probably dependent on TBK1 or IKK-i [47]. This is
reviewed in more detail by Schro¨der and Bowie, also in
this issue [31].
Activation of IRF7 by TLR7 and TLR9
Plasmacytoid DCs are specialized at producing extremely
high levels of type I IFN in response to viral challenge
(reviewed in Ref. [48]). They express TLR7 and TLR9
strongly and produce large amounts of IFN-a in response
to the TLR7 ligand, single stranded viral RNA and TLR9
activators, such as DNA viruses and CpG oligonucleotides
[49–52]. However, TLR7 and TLR9 are entirely dependent
on Myd88 for signalling and do not use any of the other
TIR domain-containing adaptors. Because the induction of
type I IFNs is crucially dependent on the activation of
IRFs, this raises the intriguing question of how these
TLRs can activate IRFs without the help of TRIF.
Plasmacytoid DCs show high levels of constitutive IRF7
expression, relative to monocyte-derived DCs [53], and
two concomitant reports showed that Myd88 forms a
complex with IRF7 to trigger its activation and induce
IFN-a [54,55]. TLR7 and TLR9 are located primarily in
the intracellular endosomal compartment [56,57] and the
Myd88–IRF7 interaction takes place in the endosomal
vesicles of the plasmacytoid DCs [58] (Figure 2). The
complex must remain in the endosome for a prolonged
time period and resist transfer to lysosomal vesicles to
trigger activation of IRF7 [58]. This complex also contains
IRAK4 and TRAF6 and the ubiquitin ligase activity of the
latter is required for IRF activation [54,55]. Furthermore,
TLR7 and TLR9 ligands activate IRF7 in a Myd88- and
IRAK-4-dependent manner. A recent study showed that
IRAK-1 interacts directly with, and phosphorylates,
IRF7 [59] and TLR7 and TLR9 ligands are severely
impaired in their ability to activate IRF7 and induce
IFN-a in IRAK-1-deficient plasmacytoid DCs. Intrigu-
ingly, these cells show relatively normal responsiveness to
TLR7 and TLR9 ligands, with respect to NF-kB activation
and proinflammatory cytokine induction. Thus, the
certainty of a role for IRAK-1 in all Myd88-dependent
NF-kB activation has been shattered and instead a new
role for IRAK-1 in mediating TLR7 or TLR9 activation of
IRF7 is being championed.
It is unclear whether or not IRAK-1 is the direct kinase
for IRF7. It was not possible to show endogenous
phosphorylation of IRF7 by IRAK-1 [59]. It is probable
that IRF7 activation by IRAK-1 is independent of TBK1
and IKK-I because plasmacytoid DCs derived from mice
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Figure 2. Activation of NF-kB and IRF7 by TLR7 and TLR9. TLR7 and TLR9 are localized in the endosomes of plasmacytoid DCs. Both TLR7 and TLR9 use a Myd88-dependent
but IRAK-1-independent pathway to activate NF-kB. This results in the phosphorylation (P) of the inhibitory IkB proteins enabling the translocation of NF-kB into the nucleus.
The most common form of active NF-kB is a heterodimer consisting of the protein subunits p50 and p65 and this complex induces the expression of proinflammatory genes.
TLR7 and TLR9 use a Myd88- and IRAK-1-dependent pathway to phosphorylate IRF7, leading to its nuclear translocation and the induction of type I IFN genes.
Review TRENDS in Immunology Vol.26 No.9 September 2005 473deficient in TBK1 or IKK-i show normal responsiveness to
TLR9 ligands with respect to induction of IFN-a [54].
However, this study does not exclude the possibility of
functional redundancy between TBK1 and IKK-i. This can
be addressed by assessing TLR9 induction of IFN-a in
IKKiK/KTBK1K/Kmice. Notably, the inability of Myd88 to
activate TBK1 or IKK-i favours TBK1- or IKK-i-indepen-
dent activation of IRF7 by IRAK-1.
Interestingly, although Myd88 interacts with, and acti-
vates, IRF7, it fails to interact with, or activate, IRF3.
Thus, in plasmacytoid DCs, IRF7 is the key regulator of
type I IFN production. This has been confirmed recently
with the generation of mice deficient in the Irf7 gene [60].
Plasmacytoid DCs derived from these mice are completely
non-responsive to TLR7 and TLR9 ligands with respect to
induction of IFN-a, whereas induction is normal in
plasmacytoid DCs from IRF3-deficient mice. These find-
ings indicate strongly that IRF7 is essential whereas IRF3
is dispensable for the induction of type I IFNs by TLR7
and TLR9 in plasmacytoid DCs.TLR signalling and IRF5
A recent report has emphasized an important role for
another member of the IRF family, IRF5, in TLRwww.sciencedirect.comsignalling [61]. The induction of proinflammatory cyto-
kines, such as TNF, IL-6 and IL-12, by TLR3, TLR4, TLR5,
TLR7 and TLR9 ligands is impaired severely in various
cells from IRF5-deficient mice. By contrast, the induction
of IFN-a by TLR9 in plasmacytoid DCs from these mice is
unaffected. Takaoka et al. [61] propose that IRF5 is
involved selectively in the induction of proinflammatory
cytokines by virtually all TLRs and this is consistent with
the increased resistance of Irf5K/K mice to lethal shock
induced by unmethylated DNA and LPS. Furthermore,
putative IRF5-binding sites are identifiable in the pro-
moters of several genes encoding proinflammatory cyto-
kines. Because NF-kB sites are also present in these
promoters and NF-kB is universally activated by all TLRs,
IRF5 and NF-kB might enjoy a close relationship in terms
of conjoint activation and functional co-operativity at their
target promoters.
IRF5 associates with both Myd88 and TRAF-6 and
ligands for TLR4 and TLR9 promote nuclear translocation
of IRF5 in a Myd88-dependent manner [61] (Figure 3).
However, many of the downstream mediators of the IRF5
pathway await identification. Although IRF-5 is phos-
phorylated by TBK1 and IKK-i, this phosphorylation does
not lead to IRF-5 nuclear translocation or activation [62].
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Figure 3. Activation of NF-kB and IRF5 by TLR signalling. Most TLRs use a Myd88-dependent pathway to activate NF-kB. This results in the phosphorylation (P) of the
inhibitory IkB proteins, enabling the translocation of NF-kB into the nucleus. The most common form of active NF-kB is a heterodimer consisting of the protein subunits p50
and p65 and this complex induces the expression of proinflammatory genes. Many TLRs can also use aMyd88- and IRAK-1-dependent pathway to activate IRF5, leading to its
nuclear translocation and co-operation with NF-kB in the induction of proinflammatory genes.
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pathway used by TLR7 and TLR9 in activating IRF7.
Indeed, a recent report has shown an important role for
IRAK-1 and TRAF-6 in TLR7 activation of IRF5 [63].
However, there are obvious differences between the
Myd88 activation of IRF5 and IRF7. The former is pro-
moted by most, if not all, TLRs, whereas the latter is more
restricted to TLR7 and TLR9. Furthermore, the mechan-
ism underlying TLR3 activation of IRF5 awaits charac-
terisation. TLR3 does not use Myd88 and thus IRF5 might
also be subject to regulation in a Myd88-independent
manner. However, Schoenemeyer et al. [63] contends
that TLR3 does not activate IRF5 and this controversy
awaits further clarification.Concluding remarks
The last two years have witnessed an enormous jump in
our understanding of the role of IRFs in TLR biology and
in the delineation of the TLR signal transduction path-
ways that regulate IRF activation. Many of the signalling
molecules are shared with the NF-kB pathway and this is
hardly surprising because the co-ordinated activation of
IRF3, IRF7 and NF-kB provides for maximal induction
of type I IFNs, whereas conjoint activation of IRF5 andwww.sciencedirect.comNF-kB ensures functional co-operativity at the promoters
of proinflammatory genes. Furthermore, it is becoming
increasingly evident that different members of the IRF
family are involved in controlling the expression of
different profiles of genes by TLRs, and this might be
crucial in ensuring the expression of appropriate gene
profiles in response to specific pathogens. However, the
molecular basis to this specificity is far from understood
and many questions require addressing. Myd88 promotes
activation of IRF7 and induction of type I IFN in response
to TLR7 and TLR9; however, it is currently unclear why
other TLRs, such as TLR2, which also use Myd88, fail to
induce IFN.
Also, why have several signalling pathways evolved to
activate the same IRF transcription factor? TLR3 and
TLR4 use the TRIF–TBK1 (IKKi) axis, whereas TLR7 and
TLR9 use the Myd88–IRAK4–IRAK-1–TRAF-6 cascade to
activate IRF7. One plausible proposal is that the host uses
two different sensing systems to detect different virus
types but both culminate in a similar antiviral response.
Regardless of the answers to these and other questions, it
is clear that TLR regulation of IRFs is crucially important
in regulating the expression of genes that mediate innate
and adaptive immunity. Furthermore, this area offers
Review TRENDS in Immunology Vol.26 No.9 September 2005 475much potential in terms of therapeutic exploitation. A
recent report has indicated that TLR9-induced type I IFN
is protective from colitis [64]. It is clear that the further
clarification of the molecular basis of the activation of IRF
members by TLRs is a worthwhile goal.
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